Univ Sousse, Ibn El Jazzar Fac Med Sousse, Sousse, Tunisia..
Univ Bergen, Fac Med, Dept Clin Sci, Bergen, Norway..
KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, India..
KEM Hosp Res Ctr, Vadu Rural Hlth Program, Pune, India.;Dr DY Patil Med Coll Hosp & Res Ctr, Pune, India..
Univ Sousse, Fac Med Sousse, LR19ES09, Sousse 4000, Tunisia..
Univ Iceland, Fac Med, Reykjavik, Iceland.;Landspitali Natl Univ Hosp Iceland, Dept Nephrol, Reykjavik, Iceland..
Natl Hlth Lab, Khartoum, Sudan..
Aga Khan Univ, Dept Community Hlth Sci, Karachi, Pakistan..
Sherikashmir Inst Med Sci, Srinagar, J&K, India..
Obafemi Awolowo Univ, Ife, Osun, Nigeria..
JSSAHER, JSS Med Coll, Dept Resp Med, Mysuru, India..
RCSI & UCD Malaysia Campus, George Town, Penang, Malaysia..
Polytech Lisbon, Lisbon Sch Hlth Technol, Lisbon, Portugal..
Santa Maria Local Hlth Unit, Pulmonol Dept, Lisbon, Portugal.;Lisbon Univ, Inst Environm Hlth, Lisbon Med Sch, Lisbon, Portugal..
Univ Kentucky, Lexington, KY USA.;COPD Fdn, Miami, FL USA..
Fac Med & Pharm Med Dent, Rebat, Morocco.;CHU Hassan II Fes, Ctr Med, Univ Sommeil & Specialiste Pneumol, Fes, Morocco..
Sidi Mohamed Ben Abdellah Univ, Fac Med Pharm & Dent, Epidemiol & Res Hlth Sci Lab, Fes, Morocco.;Hassan II Univ Hosp Ctr Fez, Fes, Morocco..
Jagiellonian Univ, Coll Med, Ctr Evidence Based Med, Krakow, Poland..
Univ Liverpool Liverpool Sch Trop Med, Pembroke Pl, Liverpool, England..
Maastricht Univ, Med Ctr, Maastricht, Netherlands..
Natl Hlth Lab, Khartoum, Sudan..
Maastricht Univ, Med Ctr, Maastricht, Netherlands.;Ludwig Boltzmann Inst Lung Hlth, Vienna, Austria..
King Saud Bin Abdulaziz Univ Hlth Sci, Riyadh, Saudi Arabia.;King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia..
Univ Cambridge, Cambridge, England.;Liverpool Univ Hosp NHS Fdn Trust, Liverpool, England..
RCSI & UCD Malaysia Campus, George Town, Penang, Malaysia..
Natl Hlth Lab, Khartoum, Sudan..
Paracelsus Med Univ, Dept Pulm Med, Salzburg, Austria..
Ctr Hosp Univ Lisboa Cent, Pulmonol Dept, Lisbon, Portugal.;NOVA Univ Lisbon, NOVA Med Sch, Lisbon, Portugal..
Imperial Coll London, Natl Heart & Lung Inst, 1B Manresa Rd, London SW3 6LR, England..
Imperial Coll London, Natl Heart & Lung Inst, 1B Manresa Rd, London SW3 6LR, England.;NIHR Imperial Biomed Res Ctr, London, England..
Background: Bronchodilator responsiveness testing is mainly used for diagnosing asthma. We aimed to investigate whether it is associated with progression to chronic airflow obstruction over time.
Methods: The multinational Burden of Obstructive Lung Disease cohort study surveyed adults, aged 40 years and above, at baseline and followed them up after a mean of 9.1 years. Recruitment took place between January 2, 2003 and December 26, 2016. Follow-up measurements were collected between January 29, 2019 and October 24, 2021. On both occasions, study participants provided information on respiratory symptoms, health status and several environmental and lifestyle exposures. They also underwent pre- and post-bronchodilator spirometry. We defined bronchodilator responsiveness at baseline using the American Thoracic Society and European Respiratory Society (ATS/ERS) 2022 definition, and the presence of chronic airflow obstruction at follow-up as a post-bronchodilator forced expiratory volume in 1 s to forced vital capacity ratio (FEV1/FVC) less than the lower limit of normal. We used multi-level regression models to estimate the association between baseline bronchodilator responsiveness and incident chronic airflow obstruction. We stratified analyses by gender and performed a sensitivity analysis in never smokers.
Findings: We analysed data from 3701 adults with 56% being women. Compared to those without bronchodilator responsiveness at baseline, those with bronchodilator responsiveness had 36% increased risk of developing chronic airflow obstruction (RR: 1.36, 95%CI 1.04, 1.80). This effect was stronger in women (RR: 1.45, 95%CI 1.09, 1.91) than men (RR: 1.07, 95%CI 0.51, 2.24). Never smokers with bronchodilator responsiveness also were at greater risk of incident chronic airflow obstruction (RR: 1.48, 95%CI 1.01, 2.20).
Interpretation: Bronchodilator responsiveness appears to be a risk factor for incident chronic airflow obstruction. It is important that future studies in other large population-based cohorts replicate these findings.
Elsevier, 2025. Vol. 81, article id 103123